Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s Disease
At present, patients with advanced Parkinson’s disease (PD) are unsatisfactorily controlled by currently used anti-Parkinsonian dopaminergic drugs. Various studies suggest that therapeutic strategies based on nondopaminergic drugs might be helpful in PD. Zolpidem, an imidazopyridine widely used as s...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2016/2531812 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551694315028480 |
|---|---|
| author | Antonio Daniele Francesco Panza Antonio Greco Giancarlo Logroscino Davide Seripa |
| author_facet | Antonio Daniele Francesco Panza Antonio Greco Giancarlo Logroscino Davide Seripa |
| author_sort | Antonio Daniele |
| collection | DOAJ |
| description | At present, patients with advanced Parkinson’s disease (PD) are unsatisfactorily controlled by currently used anti-Parkinsonian dopaminergic drugs. Various studies suggest that therapeutic strategies based on nondopaminergic drugs might be helpful in PD. Zolpidem, an imidazopyridine widely used as sleep inducer, shows high affinity only for GABAA receptors containing the α-1 subunit and facilitates GABAergic neurotransmission through a positive allosteric modulation of GABAA receptors. Various observations, although preliminary, consistently suggest that in PD patients zolpidem may induce beneficial (and sometimes remarkable) effects on motor symptoms even after single doses and may also improve dyskinesias. Since a high density of zolpidem binding sites is in the two main output structures of the basal ganglia which are abnormally overactive in PD (internal globus pallidus, GPi, and substantia nigra pars reticulata, SNr), it was hypothesized that in PD patients zolpidem may induce through GABAA receptors an inhibition of GPi and SNr (and, possibly, of the subthalamic nucleus also), resulting in an increased activity of motor cortical areas (such as supplementary motor area), which may give rise to improvement of motor symptoms of PD. Randomized clinical trials are needed in order to assess the efficacy, safety, and tolerability of zolpidem in treating motor symptoms of PD. |
| format | Article |
| id | doaj-art-a69441008dcc454ebcfd4f1def9c9d9f |
| institution | Kabale University |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-a69441008dcc454ebcfd4f1def9c9d9f2025-02-03T06:00:53ZengWileyParkinson's Disease2090-80832042-00802016-01-01201610.1155/2016/25318122531812Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s DiseaseAntonio Daniele0Francesco Panza1Antonio Greco2Giancarlo Logroscino3Davide Seripa4Institute of Neurology, Catholic University of the Sacred Heart, 00168 Rome, ItalyGeriatric Unit and Laboratory of Gerontology and Geriatrics, Department of Medical Sciences, IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, 71013 Foggia, ItalyGeriatric Unit and Laboratory of Gerontology and Geriatrics, Department of Medical Sciences, IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, 71013 Foggia, ItalyNeurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, and Sense Organs, University of Bari Aldo Moro, 70121 Bari, ItalyGeriatric Unit and Laboratory of Gerontology and Geriatrics, Department of Medical Sciences, IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, 71013 Foggia, ItalyAt present, patients with advanced Parkinson’s disease (PD) are unsatisfactorily controlled by currently used anti-Parkinsonian dopaminergic drugs. Various studies suggest that therapeutic strategies based on nondopaminergic drugs might be helpful in PD. Zolpidem, an imidazopyridine widely used as sleep inducer, shows high affinity only for GABAA receptors containing the α-1 subunit and facilitates GABAergic neurotransmission through a positive allosteric modulation of GABAA receptors. Various observations, although preliminary, consistently suggest that in PD patients zolpidem may induce beneficial (and sometimes remarkable) effects on motor symptoms even after single doses and may also improve dyskinesias. Since a high density of zolpidem binding sites is in the two main output structures of the basal ganglia which are abnormally overactive in PD (internal globus pallidus, GPi, and substantia nigra pars reticulata, SNr), it was hypothesized that in PD patients zolpidem may induce through GABAA receptors an inhibition of GPi and SNr (and, possibly, of the subthalamic nucleus also), resulting in an increased activity of motor cortical areas (such as supplementary motor area), which may give rise to improvement of motor symptoms of PD. Randomized clinical trials are needed in order to assess the efficacy, safety, and tolerability of zolpidem in treating motor symptoms of PD.http://dx.doi.org/10.1155/2016/2531812 |
| spellingShingle | Antonio Daniele Francesco Panza Antonio Greco Giancarlo Logroscino Davide Seripa Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s Disease Parkinson's Disease |
| title | Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s Disease |
| title_full | Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s Disease |
| title_fullStr | Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s Disease |
| title_full_unstemmed | Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s Disease |
| title_short | Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s Disease |
| title_sort | can a positive allosteric modulation of gabaergic receptors improve motor symptoms in patients with parkinson s disease the potential role of zolpidem in the treatment of parkinson s disease |
| url | http://dx.doi.org/10.1155/2016/2531812 |
| work_keys_str_mv | AT antoniodaniele canapositiveallostericmodulationofgabaergicreceptorsimprovemotorsymptomsinpatientswithparkinsonsdiseasethepotentialroleofzolpideminthetreatmentofparkinsonsdisease AT francescopanza canapositiveallostericmodulationofgabaergicreceptorsimprovemotorsymptomsinpatientswithparkinsonsdiseasethepotentialroleofzolpideminthetreatmentofparkinsonsdisease AT antoniogreco canapositiveallostericmodulationofgabaergicreceptorsimprovemotorsymptomsinpatientswithparkinsonsdiseasethepotentialroleofzolpideminthetreatmentofparkinsonsdisease AT giancarlologroscino canapositiveallostericmodulationofgabaergicreceptorsimprovemotorsymptomsinpatientswithparkinsonsdiseasethepotentialroleofzolpideminthetreatmentofparkinsonsdisease AT davideseripa canapositiveallostericmodulationofgabaergicreceptorsimprovemotorsymptomsinpatientswithparkinsonsdiseasethepotentialroleofzolpideminthetreatmentofparkinsonsdisease |